Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cabiralizumab by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Cabiralizumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
Cabiralizumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...